According to Repligen 's latest financial reports the company's current revenue (TTM) is $0.60 B. In 2022 the company made a revenue of $0.80 B an increase over the years 2021 revenue that were of $0.67 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.63 B | -20.31% |
2022 | $0.80 B | 19.54% |
2021 | $0.67 B | 83.08% |
2020 | $0.36 B | 35.53% |
2019 | $0.27 B | 39.28% |
2018 | $0.19 B | 37.38% |
2017 | $0.14 B | 35.1% |
2016 | $0.10 B | 25.14% |
2015 | $83.53 M | 31.45% |
2014 | $63.54 M | -6.78% |
2013 | $68.16 M | 9.48% |
2012 | $62.26 M | |
2010 | $26.25 M | 26.89% |
2009 | $20.69 M | -26.28% |
2008 | $28.06 M | 42.52% |
2007 | $19.69 M | 48.52% |
2006 | $13.26 M | 1.84% |
2005 | $13.02 M | 53.56% |
2004 | $8.47 M | 23.81% |
2003 | $6.84 M | -5.49% |
2002 | $7.24 M | 99.57% |
2001 | $3.63 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 9,529.93% | ๐บ๐ธ USA |
Thermo Fisher Scientific TMO | $42.85 B | 6,955.23% | ๐บ๐ธ USA |
General Electric GE | $69.52 B | 11,344.56% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 7,395.93% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $0.17 B | -70.99% | ๐บ๐ธ USA |
Novavax NVAX | $0.69 B | 14.16% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $1.98 B | 226.28% | ๐บ๐ธ USA |
Bio-Techne TECH | $1.14 B | 88.49% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.47 B | 306.89% | ๐บ๐ธ USA |
Charles River Laboratories
CRL | $4.12 B | 579.79% | ๐บ๐ธ USA |